Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Urologe A ; 50(2): 197-204, 2011 Feb.
Artigo em Alemão | MEDLINE | ID: mdl-21161158

RESUMO

BACKGROUND: The aim of this study was to assess the frequency of sexual intercourse (SI) in couples whose men had undergone nerve-sparing radical prostatectomy. METHOD: From February 2007 to March 2008, 25 patients and their partners were asked preoperatively and 6 and 12 months postoperatively about their real and desired frequency of SI and about their satisfaction with their sex lives. RESULTS: When questioned 6 and 12 months postoperatively, patients reported higher frequencies of sexual intercourse than their female partners did (6 months: mean 4.9 vs 4.2 and 12 months: mean 4.1 vs 3.7). At both dates the frequency of SI desired by the men was on average 7.4 vs 5.5 and 5.1 by the female partners. The women appeared to be more satisfied with their sex lives than the patients (6 months: 71 vs 56% and 12 months: 67 vs 57%). CONCLUSION: Patients and their partners differ in their appraisals of sex life and SI. Therefore it is important to consider perceptions of both partners in preoperation discussions.


Assuntos
Coito/psicologia , Prostatectomia/psicologia , Comportamento Sexual/psicologia , Parceiros Sexuais/psicologia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
2.
J Neurochem ; 90(1): 9-18, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15198662

RESUMO

Formation of neurites and their differentiation into axons and dendrites requires precisely controlled changes in the cytoskeleton. While small GTPases of the Rho family appear to be involved in this regulation, it is still unclear how Rho function affects axonal and dendritic growth during development. Using hippocampal neurones at defined states of differentiation, we have dissected the function of RhoA in axonal and dendritic growth. Expression of a dominant negative RhoA variant inhibited axonal growth, whereas dendritic growth was promoted. The opposite phenotype was observed when a constitutively active RhoA variant was expressed. Inactivation of Rho by C3-catalysed ADP-ribosylation using C3 isoforms (Clostridium limosum, C3(lim) or Staphylococcus aureus, C3(stau2)), diminished axonal branching. By contrast, extracellularly applied nanomolar concentrations of C3 from C. botulinum (C3(bot)) or enzymatically dead C3(bot) significantly increased axon growth and axon branching. Taken together, axonal development requires activation of RhoA, whereas dendritic development benefits from its inactivation. However, extracellular application of enzymatically active or dead C3(bot) exclusively promotes axonal growth and branching suggesting a novel neurotrophic function of C3 that is independent from its enzymatic activity.


Assuntos
Axônios/fisiologia , Dendritos/fisiologia , Hipocampo/fisiologia , Neurônios/fisiologia , Proteínas rho de Ligação ao GTP/metabolismo , ADP Ribose Transferases/genética , ADP Ribose Transferases/metabolismo , ADP Ribose Transferases/farmacologia , Adenosina Difosfato Ribose/metabolismo , Animais , Axônios/efeitos dos fármacos , Axônios/enzimologia , Toxinas Botulínicas/genética , Toxinas Botulínicas/metabolismo , Toxinas Botulínicas/farmacologia , Células Cultivadas , Dendritos/efeitos dos fármacos , Dendritos/enzimologia , Técnicas de Transferência de Genes , Genes Dominantes , Hipocampo/enzimologia , Hipocampo/ultraestrutura , Isoenzimas/genética , Isoenzimas/metabolismo , Isoenzimas/farmacologia , Camundongos , Camundongos Endogâmicos , Neurônios/enzimologia , Neurônios/ultraestrutura , Fenótipo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/farmacologia , Proteínas rho de Ligação ao GTP/antagonistas & inibidores , Proteínas rho de Ligação ao GTP/genética
3.
J Hematother Stem Cell Res ; 11(2): 429-35, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11983115

RESUMO

Various attempts have been made to standardize and improve the reproducibility of flow cytometric determination of CD34+ hematopoietic progenitor cells. It is still not clear, however, whether the quantification of CD34+ cells in a stem cell graft should be done before or after cryopreservation. To address this issue, we investigated 78 unselected and 32 immunomagnetically selected autologous and allogeneic leukapheresis products (LA) before and after cryopreservation using pilot vials. Cell numbers were quantified within a Neubauer chamber, and CD34+ content was determined by flow cytometry; propidium iodide staining was used to exclude dead cells from analysis. Before freezing, the mean viable CD34 cell content in the unselected samples was 1.22% and increased after thawing to a mean of 2.16% of viable cells. Taking into account cell loss and cell death, the overall recovery of viable cells was 64.5%; all CD34+ cells could be recovered. Mean purity in the CD34-selected cell fraction was 85% (48-97) before and 91.3% (67-99) after thawing. The number of viable cells was 86.8% before and 86.1% after freezing with a 93.9% recovery of total cells. This leads to a mean 93.7% (SD +/- 23.1) recovery of viable cells and 100% (SD +/- 22.3) recovery of viable CD34+ cells. There was no significant difference in tolerance to freeze/thaw stress between cells from heavily pretreated autologous patients and healthy allogeneic donors. Our data show that freezing significantly increases the percentage of CD34(+) cells in unmanipulated LA, probably due to the death of granulocytes and mononuclear cells (MNCs). Nevertheless, the overall number of viable CD34+ cells in unselected as well as selected samples remains unchanged. Thus, CD34 data from different laboratories, for example, within multicenter trials, should be comparable independent of the different time points of acquisition.


Assuntos
Antígenos CD34/análise , Criopreservação , Transplante de Células-Tronco Hematopoéticas/métodos , Estudos de Casos e Controles , Contagem de Células , Sobrevivência Celular , Citometria de Fluxo , Transplante de Células-Tronco Hematopoéticas/normas , Humanos , Separação Imunomagnética , Leucaférese/métodos , Neoplasias/terapia , Estudos Retrospectivos , Resultado do Tratamento
5.
Bone Marrow Transplant ; 22(11): 1077-85, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9877270

RESUMO

The homing of hematopoietic precursor cells (HPC) within the bone marrow is most likely to be mediated by specific adhesion via surface receptors to cellular and extracellular matrix (ECM) components and to be regulated by cytokines. We investigated the effects of serum and cytokines on the expression of adhesion molecules on cryopreserved and fresh peripheral blood-derived progenitor cells (PBPC) and on the adhesion of PBPC to various ECM proteins. PBPC were collected from patients by leukapheresis during G-CSF-supported recovery from conventional cancer chemotherapy. Freezing markedly reduced the fraction of CD34+ cells with L-selectin (CD62L) expression from 62 to 11% and also diminished the fluorescence intensity for the integrin subunits CD29 and CD49d on CD34+ cells. A 14 h incubation of thawed PBPC with serum induced re-expression of adhesion molecules. The addition of the cytokine cocktails (G-CSF + SCF + IL-3 + IL-11 or IL-4 + IL-1beta + IFN-gamma) or MGDF, however, exerted no effects in addition to serum alone. Furthermore, when compared to serum alone, the addition of cytokine cocktails or MGDF did not alter the fraction of fresh PB-CD34+ cells adhering to collagen I, collagen IV, fibronectin, laminin or vitronectin. HPC adhesion to ECM components might be refractory to short-term alterations of the cytokine environment. Alternatively, longer incubation times or other cytokines may be necessary to modulate the expression of adhesion molecules on hematopoietic progenitor cells or adhesion itself under ex vivo conditions.


Assuntos
Antígenos CD34/metabolismo , Moléculas de Adesão Celular/metabolismo , Células-Tronco Hematopoéticas/imunologia , Adesão Celular , Criopreservação , Meios de Cultura , Citocinas/farmacologia , Proteínas da Matriz Extracelular/metabolismo , Citometria de Fluxo , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/citologia , Humanos , Técnicas In Vitro , Neoplasias/patologia , Neoplasias/terapia
6.
Bone Marrow Transplant ; 18(3): 549-57, 1996 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8879616

RESUMO

One reason for relapse after high-dose tumor therapy with subsequent autologous stem cell transplantation is tumor cell contamination of the graft. Removal of tumor cells from bone marrow grafts by chemopurging with the ether lipid edelfosine has been established as an effective and simple method. When compared with bone marrow derived grafts, progenitor cells from peripheral blood have considerably reduced the haematological recovery times. However, this advantage is put at risk by the nonspecific haematotoxic activity of the purging agent. We therefore compared the in vitro recovery of peripheral blood derived progenitor cells (PBPC) from either non-purged (n = 41) or purged (75 micrograms/ml of ether lipid for 4 h at 37 degrees C, n = 48) leukapheresis products. The recovery of CFU-GM after cryopreservation was 63 +/- 4% without and 48 +/- 3% with purging (P = 0.007). After high-dose therapy, patients (n = 37) received similar amounts of either non-purged (n = 17) or purged (n = 20) autologous PBPC. The median haematological recovery times (non-purged vs purged) to > 500 WBC/microlitres were 9.0 vs 8.5 days after transplantation, to > 2000 PMN/microlitres 10.5 vs 10.0 days, and to > 50,000 PLT/microlitres 15.5 vs 14.0 days. All differences were statistically not significant. We conclude that ether lipid purging of PBPC leads to a significant, however tolerable loss of progenitor cells in vitro, and that haematological recovery times after high-dose therapy are identically short, provided similar amounts of PBPC are reinfused.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/efeitos dos fármacos , Lisofosfolipídeos/farmacologia , Neoplasias/terapia , Adulto , Idoso , Antígenos CD34/análise , Criopreservação , Humanos , Leucaférese , Pessoa de Meia-Idade , Neoplasias/sangue
7.
Cancer Res ; 56(15): 3583-8, 1996 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-8758930

RESUMO

We tested the influence of recombinant human interleukin (rhIL)-l3 and rhIL-4 on clonal growth of human breast cancer cell lines. rhIL-13 and rhIL-4 inhibited clonal growth of three of nine lines to approximately 50% of controls (ED50, 0.5 ng/ml). rhIl-13 reduced [3H]thymidine incorporation in all three cell lines: two showing a minor (84% and 83% of controls) and one showing a major response (25% of control). Both cytokines markedly reduced serum-induced G(0/1) exit (approximately 25% versus 60%). 125I-labeled interleukin (IL) 13 binding assays revealed high-affinity binding sites for IL-13 on two of the three responding cell lines (KD approximately 60 pM). (Y124D)IL-4 effectively antagonized all effects of rhIl-13 and rhIL-4, arguing for shared receptor components between them. However, neither rhIl-4 nor (Y124D) IL-4 could displace 125I-labeled IL-13 from binding, although unlabeled rhIL-13 effectively did so. Using reverse transcription-PCR, we studied the expression of the common gamma chain (gammac) in responding cell lines, putatively being shared between IL-4 receptor and IL-13 receptor; none of the three cell lines express gammac. In conclusion, we demonstrate antiproliferative effects of IL-4 and IL-13 on carcinoma cells which express IL-13 binding sites without participation of gammac.


Assuntos
Antineoplásicos/farmacologia , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Interleucina-13/farmacologia , Animais , Antígenos CD/metabolismo , Antineoplásicos/metabolismo , Sequência de Bases , Sítios de Ligação , Células CHO , Ciclo Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Cricetinae , DNA de Neoplasias/biossíntese , Humanos , Interleucina-13/metabolismo , Subunidade alfa1 de Receptor de Interleucina-13 , Interleucina-4/farmacologia , Radioisótopos do Iodo , Dados de Sequência Molecular , Receptores de Interleucina/metabolismo , Receptores de Interleucina-13 , Receptores de Interleucina-4 , Proteínas Recombinantes/farmacologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Células Tumorais Cultivadas
8.
J Hematother ; 4(6): 539-44, 1995 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8846014

RESUMO

Immunomagnetic separation using anti-CD34 monoclonal antibodies and paramagnetic microspheres has been used to enrich hematopoietic stem cells from human bone marrow, whole cord blood, or mobilized peripheral blood mononuclear cell collections. The aim of the present study was to compare the efficacy of two different CD34+ cell selection techniques in enriching CD34+ cells from mobilized fresh peripheral blood mononuclear cells. Using the magnetic cell sorter (MACS), the final product purity was 74.1% CD34+ cells (starting population 2.3% +/- 3.3%) with a 60.3% CD34+ cell yield. Using Dynabeads and subsequent chymopapain incubation for releasing the target cells from the beads (Isolex system), the released cells contained 83.3% CD34+ cells (starting population 1.2% +/- 0.7%) with a 43.4% yield. These results indicate that CD34+ cells can be isolated with high purity from fresh leukapheresis products using both immunomagnetic techniques.


Assuntos
Antígenos CD34 , Transplante de Células-Tronco Hematopoéticas/métodos , Separação Imunomagnética/métodos , Leucócitos Mononucleares/patologia , Células-Tronco Hematopoéticas/imunologia , Células-Tronco Hematopoéticas/patologia , Humanos , Leucócitos Mononucleares/imunologia
9.
Am J Kidney Dis ; 25(2): 291-6, 1995 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-7847357

RESUMO

Calcitriol is increasingly used for therapy of secondary hyperparathyroidism in patients with end-stage renal disease. Its therapeutic efficacy, however, often has been limited by the associated increase in intestinal calcium and phosphorus absorption. Previous studies reported that these side effects could be avoided by intermittent administration of calcitriol in high doses, subsequently referred to as pulse therapy. The present study was designed to investigate pulse oral calcitriol therapy in a patient subgroup especially susceptible to the development of hypercalcemia and hyperphosphatemia under standard continuous calcitriol treatment. We examined 15 peritoneal dialysis patients with moderate degrees of hyperparathyroidism (intact parathyroid hormone [iPTH] levels, 150 to 903 pg/mL) ingesting between 1.5 and 6 g of calcium salts as the sole phosphate binders. Treatment consisted of 0.5 microgram calcitriol twice weekly. Eight of these patients had been previously converted to low calcium dialysate to tolerate the necessary doses of phosphate-binding calcium salts. During the study period, comprising 8 pretreatment weeks and 8 weeks of therapy, dialysates and doses of calcium salts were not changed, so that only calcitriol influenced the determined parameters. As expected, iPTH levels decreased rapidly in all patients (P < 0.0001). However, within 4 weeks of treatment a marked increase in calcium phosphorus products was observed (P < 0.0001). Overt hypercalcemia developed in five patients. We concluded that pulse oral calcitriol has to be carefully monitored in peritoneal dialysis patients receiving high doses of calcium salts because of the increased risk for hypercalcemia and hyperphosphatemia.


Assuntos
Calcitriol/administração & dosagem , Hiperparatireoidismo Secundário/tratamento farmacológico , Diálise Peritoneal Ambulatorial Contínua , Administração Oral , Adulto , Calcitriol/efeitos adversos , Cálcio/sangue , Esquema de Medicação , Humanos , Hipercalcemia/sangue , Hipercalcemia/induzido quimicamente , Hiperparatireoidismo Secundário/sangue , Hiperparatireoidismo Secundário/etiologia , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fosfatos/sangue
11.
Rofo ; 148(3): 314-8, 1988 Mar.
Artigo em Alemão | MEDLINE | ID: mdl-2832898

RESUMO

The authors studied the influence of perception time on the quantified image quality of radiographs, using as an experimental basis the target presentation time during which there was no active involvement of the observer. No change in the influence on the observer was seen down to an observation time of 1 sec.; there was a slight but practically negligible drop on further reduction to 0.5 sec. At 0.1 sec. there was a drop that would have been approximately compensated by a contrast enhancement of object detail to about twice the original value. The influence of the perception time was placed in relation to an example of the influence of structured noise on the detection performance. This influence proved to be significantly greater than that of time. A comparison of the concept of "conspicuity" as defined by Revesz and Kundel was set in relation to the term "Auffälligkeit" ("distinctiveness") coined by Stender. It was established that the quality reserve QR after Borcke corresponds to "Auffälligkeit" as defined by Stender and should best be separated from image quality changes dues to the influence of structured noise on the detection of radiological abnormalities.


Assuntos
Radiografia , Percepção Visual , Humanos , Estatística como Assunto , Fatores de Tempo
12.
Derm Beruf Umwelt ; 28(4): 118, 1980.
Artigo em Alemão | MEDLINE | ID: mdl-7439033

RESUMO

In a 60-year-old man a mycosis of hands and feet spreading to other regions of the skin was treated with various modern antimycotic ointments. During treatment the status of the skin did not improve. In a patch-test hypersensitivity (type IV reaction according to Coombs and Gell) to miconazole, econazole and tolciclate was found, which is rare in imidazole derivatives.


Assuntos
Hipersensibilidade a Drogas/diagnóstico , Imidazóis/efeitos adversos , Econazol/efeitos adversos , Econazol/uso terapêutico , Dermatoses da Mão/tratamento farmacológico , Humanos , Imidazóis/uso terapêutico , Masculino , Miconazol/efeitos adversos , Miconazol/uso terapêutico , Pessoa de Meia-Idade , Micoses/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...